34 reports

The primary outcome measures of this study are to asses the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies)or assessment of the incidence of pneumonitis.

  • Cancer
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Hospital
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • Abbott Diagnostics Pipeline Products Overview

Lung Cancer PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER PRODUCT OVERVIEW PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER - PRODUCT STATUS PD-##/ PDL-

  • Cancer
  • Leukemia
  • Lung Cancer
  • Therapy
  • United States

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

BIODESIX VERISTRAT TEST IS A PREDICTIVE AND PROGNOSTIC BLOOD-BASED PROTEOMIC TEST FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER.

  • Hospital
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Cancer
  • Lung Cancer
  • North America
  • United States
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.

Median OS was ##. ## mo (median OS was not reached in the HCV and HBV cohorts) and the ##-mo OS rate was ##. ## percent.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Hospital
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Hospital
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Lung Cancer
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

THE PRIMARY OUTCOME MEASURES OF THIS STUDY ARE TO ASSES THE ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, LABORATORY RESULTS (HEMATOLOGY, SERUM BLOOD CHEMISTRY, HEPATITIS TESTS, STANDARD URINALYSIS DIPSTICK ASSESSMENT, COAGULATION STUDIES)OR ASSESSMENT OF THE INCIDENCE OF PNEUMONITIS.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies)or assessment of the incidence of pneumonitis.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Cell Therapy
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.

Dr Graham Cooke, Chief Investigator of the STOP-HCV-## clinical trial, said: " We are pleased to incorporate the Genedrive IL##B point of care genotyping test in the STOP-HCV-## clinical trial which aims to identify key markers to guide the duration of

  • Clinical Trial
  • Lung Cancer
  • Prostate Cancer
  • United States
  • AutoGenomics, Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies) or assessment of the incidence of pneumonitis.

  • Lung Cancer
  • Targeted Therapy
  • United States
  • Company Operations
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Hospital
  • Lung Cancer
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies) or assessment of the incidence of pneumonitis.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, and coagulation studies) or assessment of the incidence of pneumonit

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.

In cell-based assays, Pz-## strongly inhibited phosphorylation of all tested RET oncoproteins.

  • Lung Cancer
  • United States
  • Company Operations
  • Product Initiative
  • ARIAD Pharmaceuticals, Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, and coagulation studies) or assessment of the incidence of pneumonit

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.